Novacyt Sas · EURONEXT:ALNOV
Novacyt Sas — Novacyt — H1 2022 Earnings Presentation
22 slides from Novacyt Sas's earnings presentation, September 2022
Slide 1: 2022 Half Year Results
2022 Half Year Results September 2022 1
Slide 2: Disclaimer
Disclaimer The document attached hereto and the presentation of which it forms part (together the “Materials”) have been prepared by Novacyt S.A. (“Novacyt” or the “Company”). The Materials are confidential and personal to you and are furnished to you as background information to provide a basis for
Slide 3: Company capabilities, vision and purpose
Company capabilities, vision and purpose Our vision Committed to becoming a leading, global clinical diagnostics company in infectious diseases Company capabilities Our purpose We protect lives from invisible threats by enabling informed clinical decision-making through quality diagnostics in the ri
Slide 4: Presenters
Presenters • Appointed CEO of Novacyt in 2021 • Over 25 years of global experience in pharmaceuticals & biopharmaceutical companies • Internationally experienced, strategic business leader with strong track record in global commercialisation • Built & led multiple diverse, successful teams in dynami
Slide 5: 2022 Unaudited Half Year Results
2022 Unaudited Half Year Results 5
Slide 6: H1 2022 and post-period operational highlights
H1 2022 and post-period operational highlights • Developed semi-automated, • Completed closure of Microgen scalable workflow solution. Bioproducts and Lab21 and fully delivered restructuring programme • Accelerated menu availability with announced in July. access to >40 clinical ID assays. • Relaunc
Slide 7: H1 2022 unaudited – Profit & Loss
H1 2022 unaudited – Profit & Loss £'000 H1 2022 H1 2021 • Group revenue of £16.5m in H1 2022 compared with Continuing Operations* Consol Consol Revenue 16,508 52,201 £52.2m in H1 2021 predominantly driven by the Gross profit ** 4,010 1,177 expected decline in COVID-19 related sales. Gross profit % 2
Slide 8: H1 2022 unaudited balance sheet and cash
H1 2022 unaudited balance sheet and cash Jun-22 Dec-21 Jun-22 Dec-21 £'000 £'000 £'000 £'000 • Cash position at 30 June 2022 was £99.6m, compared with £101.7m at 31 December 2021, and the Company Goodwill 11,638 11,471 Share capital and premium 54,632 54,646 Retained earnings and remains debt free.
Slide 9: Delivery against strategy
Delivery against strategy 9
Slide 10: Corporate strategy – two key imperatives
Corporate strategy – two key imperatives Revenue Future Future outbreak outbreak COVID- 19 Global first responder 'Innovation engine' Human IVD Build Instruments the base Life sciences/RUO Time Prior to the COVID-19 pandemic, Novacyt was a £10-15m life sciences/RUO business 10 Illustrative
Slide 11: Evolving Novacyt beyond the pandemic – building the base
Evolving Novacyt beyond the pandemic – building the base Evolving beyond the pandemic to a sustainable growth business, serving high unmet needs in infectious diseases 2021 ~2026 80% COVID- < 10% COVID- 19 revenues Transition 19 revenues 20% non-COVID- > 90% non-COVID- 19 revenues 19 revenues Driver
Slide 12: Significant progress in building the base business (1)
Significant progress in building the base business (1) Strategy Actions Outcomes • Signed a global distribution agreement with • Broad, approved, clinical menu and enhanced Clonit srl with access to over 40 CE marked workflow available now in STI and in Q1 2023 clinical assays in respiratory and GI
Slide 13: Significant progress in building the base business (2)
Significant progress in building the base business (2) Strategy Actions Outcomes • Reduced active distributor network by over 75% Geographic • Deployed talent in key geographies to focus on key partners expansion • Optimising global distributor network to build • Added coverage in 18 new countries a
Slide 14: Promoting comprehensive product portfolio to drive near term growth
Promoting comprehensive product portfolio to drive near term growth MyGo, Q Series PROmate ® PathFlow ® CO-prep TM & VersaLab™ Lateral flow portfolio Simple, convenient Extensive lateral flow and digital reader for qPCR instruments, direct to PCR for near portfolio and digital clinical diagnostics l
Slide 15: Relaunching world class, broad range of research use only/life sciences assays and instrumentation
Relaunching world class, broad range of research use only/life sciences assays and instrumentation • Veterinary • Food • Environment • Human MyGo range of 16 and 32 well, open platform qPCR instruments offer an ideal solution for research customers 15
Slide 16: Investing in organic R&D and business development to expand our clinical portfolio in 4 key therapeutic areas
Investing in organic R&D and business development to expand our clinical portfolio in 4 key therapeutic areas Respiratory infections Gastrointestinal Respiratory infections infections Sexually transmitted infections COVID-19 Insect-borne viruses …and beyond ~2 years 16 under IVDR
Slide 17: Enhancing scalable, semi-automated workflow taking clinical testing to the front line
Enhancing scalable, semi-automated workflow taking clinical testing to the front line In vitro diagnostics ~90 minutes workflow "Q Series" PCR, 16 & Co-Prep™ extraction and automated Sample collection 32 well Instruments liquid handling assay set-up Convenience with walkaway time Rapid results High
Slide 18: Launching a broad menu of approved assays across respiratory, STI, GI and insect borne infections
Launching a broad menu of approved assays across respiratory, STI, GI and insect borne infections Phase 1 Phase 2 Phase 3 Chemistry supply only q16/32 instrument Full workflow supported supported (CO-Prep extraction, automation and PCR instrument validation STI Respiratory STI Clonit project runs
Slide 19: Continuing to be a global first responder in infectious diseases
Continuing to be a global first responder in infectious diseases Strong track record of being a "first responder" to disease outbreaks. Rapid response to Monkeypox and Adenovirus F41 in 2022 2014 2016 2020 Acquisition of Acquisition of Acquisition Lab21 Primerdesign of IT-IS business 2006 2009 2012
Slide 20: Three key areas of focus
Delivering on inorganic growth Objectives through business development Three key areas 1. Innovation 2. Acceleration 3. Strategy of focus Accelerating the molecular Strategic transactions/ portfolio (AMP) Innovation to in license & develop M&A to diversify and build for • Molecular assay menu disrup
Slide 21: Summary and outlook
Summary and outlook • Launch of new clinical IVD workflow, in partnership with Clonit, with access to a broad menu • Launched LFT digital reader for use in conjunction with extensive LFT menu • Re-launch of RUO portfolio and refreshing route to market with more focussed and streamlined distributors
Slide 22: info@novacyt.com novacyt.com Novacyt Group (UK)
info@novacyt.com novacyt.com Novacyt Group (UK) Unit 1,Watchmoor Point, Watchmoor Road, Camberley, Surrey, GU15 3AD, UK T +44 (0) 1276 600081 22 F +44 (0) 1276 600151